Reply to Xin Rui, Xiaoming Xu, and Bo Dai’s Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non–muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.018

IF 25.2 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-06-24 DOI:10.1016/j.eururo.2025.05.040

Thomas Dreyer, Jørgen Bjerggaard Jensen

引用次数: 0

Abstract

No Abstract

查看原文本刊更多论文

回复瑞新、徐晓明、戴波致编辑的信回复：Thomas Dreyer、Simone Brandt、Knud Fabrin等使用Xpert膀胱癌监测尿液生物标志物测试指导膀胱镜检查高度非肌肉侵袭性膀胱癌：来自随机对照DaBlaCa-15试验的结果Urol欧元。在出版社。https://doi.org/10.1016/j.eururo.2025.03.018

没有抽象的

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.